PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors

Patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a poor overall prognosis despite chemotherapy and radiotherapy (e.g., peptide receptor radionuclide therapy (PRRT)). Better treatment options are needed to improve disease regression and patient survival. The p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cells
Hlavní autoři: Chow, Zeta, Johnson, Jeremy, Chauhan, Aman, Izumi, Tadahide, Cavnar, Michael, Weiss, Heidi, Townsend, Courtney M., Anthony, Lowell, Wasilchenko, Carrigan, Melton, Matthew L., Schrader, Jörg, Evers, B. Mark, Rychahou, Piotr
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8160730/
https://ncbi.nlm.nih.gov/pubmed/34065268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10051261
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky